Lmr Partners LLP Apellis Pharmaceuticals, Inc. Transaction History

Lmr Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $1.29 Million - $2.02 Million	33,900 New	33,900 $1.3 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $2.11 Million - $3.69 Million	56,940 Added 99.67%	114,069 $6.83 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $915,089 - $3.45 Million	38,693 Added 209.88%	57,129 $2.17 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $1.41 Million - $1.72 Million	18,436 New	18,436 $1.68 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $498,660 - $841,906	-14,219 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $504,205 - $769,532	14,219 New	14,219 $722,000
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $3.72 Million - $5.95 Million	-121,111 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $3.8 Million - $8.46 Million	121,111 New	121,111 $3.99 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.